- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- January 2025
- 135 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- May 2024
- 135 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- August 2024
- 233 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- October 2024
- 250 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,176GBP
- Report
- August 2022
- 117 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- January 2024
- 395 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- April 2025
- 227 Pages
China
From €3640EUR$4,000USD£3,121GBP
- Report
- April 2025
- 114 Pages
China
From €1638EUR$1,800USD£1,404GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- October 2024
Global
From €3185EUR$3,500USD£2,731GBP
- Book
- July 2009
- 1116 Pages

Phenobarbital is a central nervous system drug used to treat seizures and insomnia. It is a barbiturate, a type of drug that acts as a sedative-hypnotic. It is also used to treat alcohol withdrawal and to prevent seizures in people with epilepsy. Phenobarbital is available in both generic and brand-name forms. It is typically taken orally, but can also be administered intravenously. Common side effects include drowsiness, dizziness, and confusion.
Phenobarbital is one of the oldest and most widely used anticonvulsant drugs. It is used to treat a variety of seizure disorders, including generalized tonic-clonic seizures, partial seizures, and status epilepticus. It is also used to treat insomnia and alcohol withdrawal.
The phenobarbital market is a part of the larger central nervous system drugs market. This market is driven by the increasing prevalence of neurological disorders, such as epilepsy, Alzheimer's disease, and Parkinson's disease. The market is also driven by the increasing demand for generic drugs, as well as the development of new drugs to treat neurological disorders.
Some companies in the phenobarbital market include Pfizer, GlaxoSmithKline, Sanofi, Novartis, and Mylan. Show Less Read more